Actively Recruiting
Phase I Study of IB-T101 Injection to Treat Adults With Advanced Clear Cell Renal Cell Carcinoma Evaluating Safety and Effectiveness
Led by Grit Biotechnology · Updated on 2026-04-14
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating IB-T101 injection in adult patients with advanced clear cell renal cell carcinoma. This open-label, single-center study focuses on assessing the safety, efficacy, and how the body processes IB-T101. The research aims to understand how this biological treatment performs in patients with advanced disease. Participants will receive IB-T101 injection as the experimental treatment. The study includes a dose escalation phase followed by a dose extension phase to explore different dosing levels. The trial is designed to monitor patients over time while they receive the study treatment. During the study, participants will be closely monitored for their response to the treatment and any side effects over a period of three years. Researchers will track the objective response rate and adverse events to evaluate the treatment. Participants health status will be regularly assessed to ensure safety and effectiveness throughout the trial period.
CONDITIONS
Brief Title
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Research Team
B
Bo Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
